BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Plasmid DNA Manufacturing Technology - Co-Developed By Boehringer Ingelheim Austria With BIA Separations


10/19/2005 5:13:05 PM

VIENNA, Austria & LJUBLJANA, Slovenia--(BUSINESS WIRE)--March 22, 2005--Boehringer Ingelheim Austria GmbH, Vienna, and BIA Separations d.o.o., Ljubljana, are pleased to announce a technological innovation in the field of plasmid DNA (pDNA) manufacture. To meet the growing need for pharmaceutical grade pDNA, Boehringer Ingelheim Austria has developed a high cell density fermentation technology achieving titers up to 1 g pDNA per Liter, and has specifically designed equipment for the automated and gentle lysis of the biomass. A key and novel element of the production process is the use of CIM Convection Interaction Media(R) short monolithic columns for the purification of pDNA. The fast separation speed, outstanding capacity, and excellent separation power of CIM(R) columns, developed by BIA Separations, allows a 15-fold increase in productivity compared to traditional supports. "Our customers clearly benefit from this new development as the process is free of antibiotics, animal-derived raw materials, enzymes and organic solvents and employs the powerful CIM(R) separation technology" says Dr. Kurt Konopitzky, Head of the Division Biopharmaceuticals/Operations at Boehringer Ingelheim Austria.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->